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ABSTRACT Measuring treatment outcome is important for successful tuberculosis (TB) control programmes. The 
purpose of this study was to examine the outcomes of various types of TB cases registered in Pakistan over a 2-year 
period and compare those outcomes among the different provinces and regions of the country. A retrospective, 
cohort study was conducted in which TB treatment outcome reports were reviewed. Of the 349 694 pulmonary 
TB cases registered in Pakistan during 2006 and 2007, 309 154 (88.4%) were treated successfully. Treatment 
success was significantly higher in new smear-positive cases and lower in retreatment cases. Among the provinces 
and regions, treatment success was significantly higher in 4 out of 8 provinces. Treatment success needs to be 
improved, particularly in retreatment cases. The national TB control programme should review the provincial 
and regional programmes and learn lessons from well-performing programmes. Patient factors that may affect 
the treatment outcome should be also studied.
1National Tuberculosis Control Programme, Islamabad, Pakistan (Correspondence to A.A. Chughtai: doctorahmad75@gmail.com).
2School of Public Health and Community Medicine; 3School of Women and Child Health, University of New South Wales, Sydney, Australia.
4World Health Organization Regional Office for the Eastern Mediterranean, Cairo, Egypt.
Received: 22/11/11; accepted: 22/04/12
2007-2006 ناتسكاب في لسلا طمانأ فلتمخ ةلجاعم لئاصح
ناخ دوممح قثاو ،واج ياه ناز ،جناو سكيلأ ،يرطنيلكام انيار ينيدناش ،تياجوش دحمأ راربأ
 لسلا تلاالح ةفلتخلما طمانلأا لئاصح لىع ف ُّرعتلل ةساردلا هذه فدتهو .لسلا ةحفاكم جمارب حاجنل ماه رمأ ةلجاعلما لئاصح سايق نإ :ةـصلالخا
 تَّ َمت ةيبارتأ ةيداعتسا ةسارد يهو .ناتسكاب في ميلاقلأاو تايلاولا فلتمخ ينب لئاصلحا كلت ةنراقم عم ْنين َمماع ىدم لىع ناتسكاب في تل ِّجُس يتلا
 ددع غلبو ،2007و 2006  ْني َمماع للاخ ناتسكاب في ةلجسم يوئر لس ةلاح 694 349  تلمشو لسلا ةلجاعم لئاصح لوح ريراقتلا ةعجارم اهيف
 .ةلجاعلما ةداعإ تلااح في ضفخأو ةخاطللا ةيبايجلإا ةديدلجا تلاالحا في لىعأ حاجنلا لّدعم ناكو ،)%88.4( 309 154 حاجنب تلجوع يتلا تلاالحا
 ةساردلا تصلخو .تايلاو 8 لصأ نم تايلاو 4 في ًايئاصحإ هب ُّدَمت ْنعُي ردقب لىعأ ةلجاعلما حاجن نأ ترهظأ دقف ميلاقلأاو تايلاولا ينب ةنراقلما امأ
 في جمابرلا ةعجارم لسلا ةحفاكلم ينطولا جمانبرلا لىع يغبني هنأو ؛ةلجاعلما ةداعإ تلااح في ماَّيسلاو ةلجاعلما حاجن تلاّدعم ينستح يغبني هنأ لىإ
.ةلجاعلما لئاصح لىع رِّثؤت دق يتلاو ضيرلماب ةقلعتلما لماوعلا ةسارد يغبني ماك ،دِّيلجا ءادلأا تاذ جمابرلا سورد نم ديفتسي نأو تايلاولاو ميلاقلأا
Résultats thérapeutiques pour les différents types de tuberculose au Pakistan en 2006 et 2007
RÉSUMÉ Mesurer les résultats thérapeutiques est important pour la réussite des programmes de lutte 
antituberculeuse. L'objectif de la présente étude était d'évaluer les résultats thérapeutiques des différents types 
de cas de tuberculose enregistrés au Pakistan au cours d'une période de deux ans et de comparer ces résultats 
avec ceux des différentes provinces et régions du pays. Une étude de cohorte rétrospective a été menée au cours 
de laquelle les rapports sur les résultats de traitement de la tuberculose ont été examinés. Sur les 349 694 cas de 
tuberculose pulmonaire enregistrés au Pakistan en 2006 et 2007, 309 154 (88,4 %) ont été traités avec succès. 
Le taux de guérison était nettement supérieur pour les nouveaux cas à frottis positif et inférieur pour les cas de 
retraitement. En outre, au niveau des provinces et des régions, il était nettement plus élevé dans 4 des 8 provinces. 
Le taux de guérison doit être amélioré, notamment pour les cas de retraitement. Le programme national de lutte 
antituberculeuse devrait revoir les programmes dans les provinces et les régions et tirer les enseignements des 
programmes performants. Les facteurs concernant le patient qui pourraient affecter les résultats du traitement 
doivent aussi être étudiés.
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Introduction
Tuberculosis (TB) is one of the 
major public health problems in Pa-
kistan. The country ranks 6th among 
the high-burden TB countries and 
harbours 63% of the disease burden 
in the Eastern Mediterranean Region. 
The incidence of smear-positive TB 
cases is 97/100 000 and the incidence 
of all types of TB cases is 231/100 000 
[1]. The Pakistan national TB control 
programme (NTP) adopted the World 
Health Organization (WHO) DOTS 
treatment strategy in 1995 [2]. After 
lapsing, the NTP was revived in 2001 
and TB was declared a national emer-
gency [3]. Since then efforts have been 
made to expand partnerships and bring 
all stakeholders on board in order to 
control this disease more effectively. 
In line with Millennium Development 
Goals the case detection rate for new 
smear-positive cases increased from 
2.8% in 2000 to 75% in 2008. The 
treatment success rate (TSR) has also 
increased from 74% in 2000 to 87% 
in 2007 and been maintained to date, 
against the target of 85% [4].
Measuring treatment outcome is 
always important for successful TB 
control programmes. Although many 
factors affect the successful outcome 
of TB treatment, the type of TB is the 
most important predictor of treatment 
outcome. The TSR is low in multi-drug 
resistant and other retreatment TB cas-
es, including cases of relapse, treatment 
after failure and treatment after default. 
Studies also show that the chances of 
being cured reduces as sputum grad-
ing increases [5] and this is particu-
larly significant in retreatment cases [6]. 
TSRs are considered good in DOTS 
areas [7]. Globally, TB is reported to 
be higher in males [8,9], but treatment 
compliance is usually higher in females 
[10–14]. Treatment outcome has been 
also assessed on the basis of treatment 
periods [15–18] and among different 
regions [16]. In most of these studies, 
the TSR and cure rate increased over 
time [17,18]. In this national study in 
Pakistan the outcome of TB cases reg-
istered from 2006–07 was assessed on 
the basis of the time period, types of TB 
and different provinces/regions.
Methods
Study design
A retrospective cohort study was con-
ducted to evaluate the factors associated 
with the outcome of TB cases registered 
in Pakistan. TB treatment outcome 
data of all provinces and regions was 
included in this study.
Data collection
TB case finding and treatment outcome 
reports were reviewed and all patients 
registered and reported during 2006– 
07 were included in the study. A total 
of 409 366 TB cases were reported dur-
ing this period, out of which 349 694 
were pulmonary and 59 772 were 
extra pulmonary. As the NTP does not 
declare the outcome of extrapulmonary 
cases only pulmonary TB cases were 
included in this study.
The NTP uses the WHO’s rec-
ommended recording and reporting 
system for TB surveillance. The WHO 
has developed a set of tools and these 
have been recently revised through a 
consultative process [19]. The NTP 
has adopted these revised recording 
and reporting tools, with some minor 
modifications, in the local context. The 
NTP has a set of nationally agreed no-
menclature and definitions for various 
treatment outcomes of the TB patients. 
The definitions used in the programme 
are compatible with international rec-
ommendations. We used the standard 
treatment outcomes: cured, treatment 
complete, died, treatment failure, de-
faulted and transferred out.
The data were analysed by type 
of TB case (new smear-positive, new 
smear-negative, relapsed, treatment af-
ter failure and treatment after default), 
year (2006 and 2007) and region [Azad 
Jammu and Kashmir Province (AJK), 
Balochistan, Federally Administered 
Tribal Areas (FATA); Northern Areas 
(NA), North-West Frontier Province 
(NWFP), Punjab, Sindh and the Fed-
eral TB control centre].
Ethical issues
Ethical clearance was obtained from the 
human research ethics advisory panel 
of University of New South Wales, 
Australia. Permission was sought from 
the NTP in the Ministry of Health, 
Pakistan, to use de-identified TB data 
for this study.
Data entry and analysis
The TB treatment outcome data of all 
districts was entered into SPSS, version 
17. All data were double-checked for er-
rors and missing values. Means and fre-
quencies were used for the description 
of various variables. Logistic regression 
was used to estimate the odds ratios 
(OR) and their 95% confidence inter-
vals (CI), with the TB treatment result 
as an outcome. First, univariate analyses 
were performed to examine the effect of 
each variable on the different outcomes 
of TB. Then multivariate logistic models 
were constructed; in the Punjab prov-
ince, new smear-positive TB cases and 
the year 2006 were reference categories. 
In all statistical tests, P-value < 0.05 was 
considered significant.
Results
A total of 349 694 pulmonary TB cases 
were included in the study: 153 063 
cases were registered in 2006 and 
196 631 cases in 2007. Among the total 
cases, most were new cases (153 590 
smear-positive and 183 448 smear-
negative); < 4% were retreatment cases 
(6839 relapsed, 1296 treatment after 
failure and 4521 treatment after default) 
(Table 1). A significant variation was 
seen in the type of TB cases registered in 
different provinces and regions. 
طسوتلما قشرل ةيحصلا ةلجلماشرع عساتلا دلجلما 
سداسلا ددعلا
537
Of the total cases registered dur-
ing 2006 and 2007 123 975 (40.1%) 
cases were cured and 185 179 (59.9%) 
completed treatment. Thus 309 154 
(88.4%) cases were classified as treat-
ment successful (Table 1). Cure and 
treatment completion rates were high 
in new TB cases and low in retreatment 
cases (relapsed, treatment after failure 
and treatment after default). Death, 
failure and default rates were high in 
retreatment cases. 
Univariate analysis showed a high 
TSR in smear-positive cases compared 
with all other types of TB (Table 2). 
New smear-negative cases were 14% 
less likely to be treated successfully than 
new smear-positive cases (OR 0.86, 
95% CI: 0.84–0.88). Among the retreat-
ment cases, TSRs were lowest for the 
treatment after default cases (OR 0.28, 
95% CI: 0.26–0.30), followed by the 
treatment after failure (OR 0.30, 95% 
CI: 0.27–0.34) and relapsed cases (OR 
0.60, 95% CI: 0.56–0.63). TSR sig-
nificantly improved in 2007 compared 
with 2006 (OR 1.34, 95 CI: 1.32–1.37). 
Compared with Punjab province, more 
cases were successfully treated in the 
NA (OR 3.55, 95% CI: 2.90–4.30), AJK 
(OR 2.21, 95% CI: 1.98–2.50), NWFP 
(OR 1.51, 95% CI: 1.46–1.58) and 
FATA (OR 1.42, 95% CI: 1.28–1.58). 
In Baluchistan, Sindh and the Federal 
TB centre, the outcome was poor when 
compared with the Punjab (Table 2).
The death rate was significantly 
lower in new smear-negative cases 
(OR 0.84, 95% CI: 0.80–0.88) and 
higher in relapsed (OR 1.62, 95% CI: 
1.43–1.83), treatment after failure (OR 
2.00, 95% CI: 1.55–2.59) and treatment 
after default cases (OR 1.7, 95% CI: 
1.46–1.98). The death rate was lower in 
2007 compared with 2006 (OR 0.996, 
95% CI: 0.995–0.997). Compared with 
Punjab, more patients died in AJK (OR 
1.69, 95% CI: 1.47–1.93), Baluchistan 
(OR 1.62, 95% CI: 1.47–1.92) and 
Sindh (OR 1.20, 95% CI: 1.14–1.27) 
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After multivariate analysis with ad-
justment for the type of TB and the 
year of registration there were no major 
changes in the ORs.
Discussion
Declaring treatment outcomes is im-
portant for monitoring the quality of 
case management and the progress of 
TB control programmes. Data from 
2006 and 2007 were analysed in this 
study. The treatment outcome was 
significantly higher in 2007 compared 
with 2006; TSRs increased and death 
rates decreased significantly in 2007. 
The TSR of new smear-positive cases 
was 74% in 2000 and this had increased 
to 91% by 2007. Data from the NTP 
Pakistan showed that the TSR of re-
treatment cases was 66% in 2002 and 
had increased to 79% in 2007 [20]. 
It is also interesting to note that the 
NTP was in the DOTS expansion 
phase from 2002 to 2005 and achieved 
100% DOTS coverage in 2005. With 
this rapid DOTS expansion, the TSR 
also increased in that time period [20]. 
Some other studies also showed that 
the DOTS population coverage had 
a significant effect on the overall TSR 
and countries with full DOTS coverage 
had an 18% higher rate of successful 
treatment [21]. 
Treatment outcome is generally 
poor in retreatment TB cases [1], par-
ticularly in cases of treatment after fail-
ure [22]. Confirming WHO data [1], 
the outcome of retreatment cases in our 
study was poorer than smear-positive 
cases. Among the retreatment cases, 
we found that successful outcome was 
worse for the cases of treatment after 
default (OR 0.33, 95% CI: 0.29–0.38) 
than treatment after failure (OR 0.28, 
95% CI: 0.26–0.30) . TSRs were high in 
smear-positive cases and this was mainly 
due to the high default rate in other types 
of TB cases. New smear-positive cases 
are usually more severe than smear-neg-
ative cases, but less severe than retreat-
ment cases. This may be a reason for the 
high number of deaths in retreatment 
cases compared with smear-positive 
cases. Among the retreatment cases, 
more cases of treatment after failure 
died (OR 1.88, 95% CI: 1.45–2.42) 
than treatment after default (OR 1.68, 
95% CI: 1.44–1.95) and relapsed cases 
(OR 1.60, 95% CI: 1.40–1.80). These 
results also highlight the possibility of 
drug resistance among treatment after 
failure cases who are sputum smear-
negative at the start of treatment and be-
come smear-positive during the course 
of treatment. Failure to treat in category 
2 also resulted in treatment failure (this 
includes smear-positive relapses, failure, 
Table 2 Multivariate analysis of treatment success rates among registered cases of pulmonary tuberculosis (TB) in Pakistan 
Variable Treatment success Univariate analysis Multivariate analysisb
Yes No
No. % No. % OR 95% CI OR 95% CI
Type of TB
New smear-positivea 137 617 89.6 15 973 10.4 1.00 – 1.00 –
New smear-negative 161 679 88.1 21 769 11.9 0.86 0.84–0.88 0.89 0.87–0.91
Relapsed 5 726 83.7 1 113 16.3 0.60 0.56–0.63 0.56 0.53–0.60
Treatment after failure 940 72.5 356 27.5 0.30 0.27–0.34 0.33 0.29–0.38
Treatment after default 3 192 70.6 1 329 29.4 0.28 0.26–0.30 0.28 0.26–0.30
Year
2006a 132 316 86.4 20 747 13.6 1.00 – 1.00 –
2007 176 838 89.9 19 793 10.1 1.34 1.32–1.37 1.35 1.32–1.38
Province
AJK 5 851 94.9 312 5.1 2.21 1.98–2.50 2.24 2.00–2.51
Balochistan 10 657 88.6 1 376 11.4 0.92 0.86–0.97 0.89 0.84–0.95
FATA 4 641 92.3 385 7.7 1.42 1.28–1.58 1.46 1.31–1.62
NA 3 241 96.8 108 3.2 3.55 2.93–4.30 3.56 2.94–4.32
NWFP 38 115 92.8 2 973 7.2 1.51 1.46–1.58 1.52 1.46–1.58
Punjaba 178 838 89.4 21 162 10.6 1.00 – 1.00 –
Sindh 62 128 85.4 10 606 14.6 0.70 0.68–0.71 0.71 0.70–0.73
Federal TBC 5 683 61.1 3 618 38.9 0.18 0.18–0.19 0.19 0.18–0.20
aReference category.  
bIn the multivariate analysis, all variables in the univariate analysis were considered. 
AJK =Azad Jammu and Kashmir region; FATA = Federally Administered Tribal Areas; NA = Northern Areas; NWFP = North-West Frontier Province; TBC = TB control 
centre. 
OR = odds ratio; CI = confidence interval.
طسوتلما قشرل ةيحصلا ةلجلماشرع عساتلا دلجلما 
سداسلا ددعلا
539
treatment after default and other smear-
positive patients who have received 
anti-TB treatment for more than 1 
month without being registered). Con-
sequently, it would appear that there 
are more chances of drug resistance in 
these cases. These cases must be offered 
drug susceptibility testing and 2nd-line 
TB drugs from the beginning of treat-
ment. The Pakistan NTP is using an 
8-month regimen and 2 drugs, isonia-
zid and ethambutol, in the continuous 
phase of category 1 cases (this includes 
new cases of pulmonary TB, whether 
smear-positive or -negative, extrapul-
monary TB and other smear-negative 
and extrapulmonary patients). Studies 
have shown that a 6-month regimen, 
which contains rifampicin, has a good 
outcome and low relapse rate. Treat-
ment failure and relapse is more com-
mon with an 8-month regimen [23]. 
Most high-burden TB countries have 
already shifted to the 6-month regimen 
containing rifampicin. It is therefore 
important to evaluate the efficacy of the 
8-month regimen that does not contain 
rifampicin in Pakistan and, importantly, 
consider the 6-month regimen, which is 
more effective.
As a whole, the TSR was good in 
most of the regions except Sindh prov-
ince and the Federal TB centre. Com-
pared with Punjab, more cases were 
successfully treated in NA, AJK, NWFP 
and FATA. In Baluchistan, Sindh and 
the Federal TB centre, the outcome was 
poor compared with Punjab. The main 
reason for the low success rate seemed 
to be the high number of default cases. 
The population of the provinces, so-
cioeconomic status and security situa-
tions are important factors to consider, 
as these can affect the default rate. At 
around 80 million people Punjab is the 
most populous province and contains 
half of the population of the Pakistan. 
The default rate was low in NA, AJK 
and FATA, presumably because the 
population is very low compared with 
Punjab. The population of NA is around 
1 million and of FATA and AJK around 
3 million. Furthermore, a poor law and 
order situation and low socioeconomic 
status may be a cause of high default 
rates. Both factors exist in Baluchistan, 
where the law and order situation is 
very poor and socioeconomic status is 
also low. The high default rate in Sindh 
is not easy to explain and the NTP 
should explore the reasons for this phe-
nomenon. The Federal TB centre is a 
specialized TB institution, affiliated with 
the Federal government, and caters for 
cases not only from the Federal capital 
but also from neighbouring districts. 
As the Federal capital is not included in 
any province and region, the data were 
collected separately. The TSR was low 
Table 3 Multivariate analysis of death rates among registered cases of pulmonary tuberculosis (TB) in Pakistan 
Variable Died Univariate analysis Multivariate analysisb
Yes No
No. % No. % OR 95% CI OR 95% CI
Type of TB
New smear-positivea 3 819 2.5 149 771 97.5 1.00 – 1.00 –
New smear-negative 3 851 2.1 179 597 97.9 0.84 0.80–0.88 0.87 0.83–0.91
Relapsed 271 4.0 6 568 96.0 1.62 1.43–1.83 1.59 1.40–1.81
Treatment after failure 63 4.9 1 233 95.1 2.00 1.55–2.59 1.88 1.45–2.42
Treatment after default 188 4.2 4 333 95.8 1.70 1.46–1.98 1.68 1.45–1.95
Year
2006a 3 926 3.0 149 170 97.0 1.00 – 1.00 –
2007 4 266 2.0 192 365 98.0 0.996 0.995–0.997 0.83 0.79–0.87
Province
AJK 234 3.8 5 929 96.2 1.69 1.47–1.93 1.65 1.45–1.89
Balochistan 440 3.7 11 593 96.3 1.62 1.47–1.92 1.57 1.42–1.74
FATA 104 2.1 4 922 97.9 0.90 0.74–1.14 0.88 0.72–1.07
NA 69 2.1 3 280 97.9 0.90 0.76–0.88 0.96 0.76–1.22
NWFP 773 1.9 40 315 98.1 0.82 0.76–0.88 0.78 0.73–0.85
Punjaba 4 575 2.3 195 425 97.7 1.00 – 1.00 –
Sindh 1 993 2.7 70 741 97.3 1.20 1.14–1.27 1.13 1.07–1.19
Federal TBC 4 0.0 9 297 100.0 0.01 0.007–0.05 0.02 0.007–0.05
aReference category.  
bIn the multivariate analysis, all variables in the univariate analysis were considered. 
AJK =Azad Jammu and Kashmir region; FATA = Federally Administered Tribal Areas; NA = Northern Areas; NWFP = North-West Frontier Province; TBC = TB control 
centre. 
OR = odds ratio; CI = confidence interval.
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and this may be due to poor case reten-
tion and a high default rate. Patients 
often come to the centre from remote 
areas and once they start improving 
they do not return. Interestingly, AJK 
had a good TSR but had a significantly 
higher number of deaths than other 
provinces. Although deaths were also 
lower in FATA and NA, this was not 
significant. Unfortunately, the causes of 
death cannot be assessed through the 
outcome data, as individual TB patients’ 
data are required for this purpose.
According to our knowledge, this 
was the first study in Pakistan to evaluate 
the outcome of TB on the basis of types 
and regions. Nevertheless it also had 
some unavoidable limitations. Firstly, 
we were restricted to using TB patients’ 
outcome reports. As individual patient 
data was not used in this study, many 
other variables which may also affect 
the treatment outcome—for example 
age, sex, sputum status and duration of 
symptoms—could not be accessed. 
Secondly, there was the possibility of 
misclassification, for example, patients 
were categorized as new or retreatment 
cases on their history of previous treat-
ment. If patients are not categorized 
properly, there is a greater chance of 
unfavourable outcomes. Thirdly, the 
causes of deaths and default were not 
given in outcome reports and death 
and default are the main reasons for low 
treatment success. It is particularly im-
portant to know whether patients died 
due to TB or to other reasons. Fourthly, 
drug susceptibility and HIV status was 
not routinely tested before the start of 
treatment and this may have affected 
the outcome of TB. Finally, these data 
were mainly obtained from the public 
sector, as very few private providers sent 
data to the NTP. The NTP has recently 
started many public–private partner-
ship ventures to involve the private sec-
tor in DOTS.
Conclusion
We found that the treatment outcome 
was generally high for new TB cases 
(smear-positive and smear-negative) 
and low for retreatment cases (relapsed, 
treatment after failure and treatment 
after default). Ways to improve TB case 
management need to be investigated 
to reduce the chances of recurrence 
and treatment failure, particularly in 
retreatment cases, perhaps by adopting 
the 6-month short-course regimen. The 
treatment outcome also varied among 
different provinces and regions. The 
NTP should review the provincial/
regional programmes and learn lessons 
from well-performing programmes. 
Defaulting from treatment was linked 
to poor outcomes in some areas. 
Causes of the high death rate in AJK 
and Baluchistan need to be explored 
and contributing factors addressed 
promptly. It is also essential to conduct 
further studies to assess the effect of 
other patient variables on the outcome 
of TB treatment.
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